MDM2 and acute myeloid leukemia: A phase Ib clinical study (NCT02670044) of combination MDM2 and BCL-2 inhibitors in relapsed or refractory AML demonstrated encouraging safety and efficacy in patients who were ineligible for cytotoxic chemotherapy [172].